CompletedNCT00481975
Rimonabant for weight and binge eating
About this title
Read the official source —Medication studyAges 18–70Multiple countriesEating disorders
Understand this study
Who was this study for?
Listed age limits: 18 years to 70 years.
- Listed locations
- Bridgewater and 6 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateAugust 2004
- Recruitment status
- Completed
- Enrollment listed in the registry
- 289
- Sponsor
- Sanofi
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States, France, Switzerland, ...
- Age range
- From 18 Years to 70 Years
- Official registry ID
- NCT00481975
- Official title
Show the full official title
A Randomized, Double-Bind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multicenter Study to Assess Efficacy and Safety of Rimonabant 20 mg Versus Placebo on Weight Loss and Frequency of Binge Episodes in Obese Patients With Food Craving
Get this study by email
Recruitment & locations
CompletedBridgewater, United States · Helsinki, Finland · Paris, France
4 more locations
- Gouda, Netherlands
- Porto Salvo, Portugal
- Bromma, Sweden
- Geneva, Switzerland
Questions about this study
Who is behind this study?
The study sponsor is Sanofi.
Did this study involve medication?
Yes. The study involved medication, including rimonabant (SR141716).
Who was this study for?
Listed age limits: 18 years to 70 years.
